Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alterity Therapeutics Ltd ADR (NQ: ATHE )

1.300 -0.020 (-1.52%)
Streaming Delayed Price Updated: 3:13 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,966
Open 1.331
Bid (Size) 1.290 (9)
Ask (Size) 1.360 (3)
Prev. Close 1.320
Today's Range 1.294 - 1.340
52wk Range 1.010 - 5.410
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Present at MST Financial Webinar
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire

Performance

YTD
-47.58%
-47.58%
1 Month
-18.50%
-18.50%
3 Month
-35.00%
-35.00%
6 Month
-23.98%
-23.98%
1 Year
-51.85%
-51.85%

More News

Read More
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.